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196Treatment of veterans with hepatitis C in the United States
Department of Veterans Affairsincorporating direct acting antivirals [7], trained hundreds of
VA health care providers to deliver anti-viral therapy, champi-
oned integrated models to address treatment-limiting comorbid-
ities [8], added dozens of clinical resources to its HCV Web site
(www.hepatitis.va.gov), and moved aggressively to increase
access to evaluation and treatment of HCV through teleconsulta-
tion models [9].
As a VA clinician who provides care for Veterans with HCV, I
am proud of VA’s HCV Program, which is recognized as a national
leader in the integrated care of patients with this disease [10].
Although there is always room for improvement in any therapeu-
tic service in any health care system, VA has been striving to deli-
ver high-quality, evidence-based care to as many Veterans with
HCV as possible, and will continue to do so.
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As Director of the National Hepatitis C Program for the United
States Department of Veterans Affairs [VA], the largest provider
of care in the United States for HCV, I would like to respond to
the statements by Dr. Bennett Cecil in the October 2012 issue
of the Journal of Hepatology about access to and quality of care
for HCV-infected Veterans in VA care [1].
1. Dr. Cecil used data from 2005 [2] as the basis for his statement
that only 12% of Veterans with HCV in VA care have received
anti-viral therapy. However, two of the references he cited
explicitly contradict that ﬁgure [3,4]. In fact, the actual pro-
portion treated is more than double that. As of September
30, 2012, internal VA data show over 25% of HCV-infected Vet-
erans in VA care having received such treatment, compared to
17% in non-VA settings [5].
2. Dr. Cecil incorrectly states that both boceprevir and telaprevir
are on the VA National Formulary; actually, only boceprevir is,
with telaprevir available for use by VA providers as a non-for-
mulary agent [6].
3. Dr. Cecil states that telaprevir is viewed as ‘‘too expensive’’ for
use by VA but did not provide any evidence for this conten-
tion. In fact, a VHA policy memorandum issued in September
2011 stipulates that cost is not to be a factor in prescribing
HCV protease inhibitors. Dr. Cecil did not provide an evi-
dence-based rationale for his preference for prescribing
telaprevir.
4. Dr. Cecil implies that he is responsible for anti-viral treatment
of almost 600 HCV patients at the Louisville VA; however,
multiple providers actually care for the patients with HCV
infection at that facility. With regard to use of triple therapy
at the Louisville VAMC, as of November 2012, 37 patients
had initiated triple therapy (36 boceprevir, 1 telaprevir). Ten
were on therapy at that time. Of the remaining 27, six
(22.2%) had achieved an SVR, seven were discontinued for lack
of efﬁcacy, six were discontinued for toxicity, and eight for
non-adherence.
5. The Louisville VAMC’s screening/evaluation process includes a
review by a clinical pharmacy specialist of drug/ drug interac-
tions, current laboratory results, and monthly monitoring of
prescription ﬁlls. Patients for whom treatment is appropriate
attend a mandatory education class and provided information
on HCV, anti-viral therapy, and drug side effects, as well as the
importance of drug compliance and obtaining repeat labora-
tory tests. In addition, a treatment plan and follow-up clinic
appointments are reviewed. This class is scheduled weekly,
but also has been done at other times at the convenience of
individual Veterans (M. Rothschild, personal communication).
Finally, and most importantly, Dr. Cecil’s assertions that ‘‘VA
has not shown enthusiasm for treating HCV patients’’ and that
it is ‘‘not going to treat very many of them’’ are incorrect. Since
FDA approved the ﬁrst direct acting anti-virals in May 2011, VA
has treated almost 4500 patients with triple therapy, spent over
$100 million in antiviral drug acquisition costs, published
updated treatment guidelines recommending use of regimensJournal of Hepatology 2013 vol. 59 j 190–199
